Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cryoballoon ablation outcomes for paroxysmal atrial fibrillation.
Angiotensin receptor blockers
Angiotensin-converting enzyme inhibitors
Cryoballoon ablation
Outcome
Paroxysmal atrial fibrillation
Journal
World journal of cardiology
ISSN: 1949-8462
Titre abrégé: World J Cardiol
Pays: United States
ID NLM: 101537090
Informations de publication
Date de publication:
26 Oct 2022
26 Oct 2022
Historique:
received:
29
05
2022
revised:
18
06
2022
accepted:
06
09
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
8
11
2022
Statut:
ppublish
Résumé
Cryoballoon ablation (CBA) is recommended for patients with paroxysmal atrial fibrillation (AF) refractory to antiarrhythmic drugs. However, only 80% of patients benefit from initial CBA. There is growing evidence that pretreatment with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) decreases the recurrence of AF postablation, particularly in nonparoxysmal AF undergoing radiofrequency ablation. The role of ACEIs and ARBs in patients with paroxysmal AF in CBA remains unknown. We decided to investigate the role of ACEIs and ARBs in preventing the recurrence of atrial arrhythmia (AA) following CBA for paroxysmal AF. To investigate the role of ACEIs and ARBs in preventing recurrence of AA following CBA for paroxysmal AF. We followed 103 patients (age 60.6 ± 9.1 years, 29% women) with paroxysmal AF undergoing CBA 1-year post procedure. Recurrence was assessed by documented AA on electrocardiogram or any form of long-term cardiac rhythm monitoring. A multivariable Cox proportional hazard model was used to assess if ACEI or ARB treatment predicted the risk of AA recurrence. After a 1-year follow-up, 19 (18.4%) participants developed recurrence of AA. Use of ACEI or ARB therapy was noted in the study population. Patients on ACEI/ARB had a greater prevalence of hypertension and coronary artery disease. On a multivariate model adjusted for baseline demographics and risk factors for AF, ACEI or ARB therapy did not prevent recurrence of AA following CBA ( In our study population, preablation treatment with an ACEI or ARB had no influence on the recurrence of AA following CBA for paroxysmal AF.
Sections du résumé
BACKGROUND
BACKGROUND
Cryoballoon ablation (CBA) is recommended for patients with paroxysmal atrial fibrillation (AF) refractory to antiarrhythmic drugs. However, only 80% of patients benefit from initial CBA. There is growing evidence that pretreatment with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) decreases the recurrence of AF postablation, particularly in nonparoxysmal AF undergoing radiofrequency ablation. The role of ACEIs and ARBs in patients with paroxysmal AF in CBA remains unknown. We decided to investigate the role of ACEIs and ARBs in preventing the recurrence of atrial arrhythmia (AA) following CBA for paroxysmal AF.
AIM
OBJECTIVE
To investigate the role of ACEIs and ARBs in preventing recurrence of AA following CBA for paroxysmal AF.
METHODS
METHODS
We followed 103 patients (age 60.6 ± 9.1 years, 29% women) with paroxysmal AF undergoing CBA 1-year post procedure. Recurrence was assessed by documented AA on electrocardiogram or any form of long-term cardiac rhythm monitoring. A multivariable Cox proportional hazard model was used to assess if ACEI or ARB treatment predicted the risk of AA recurrence.
RESULTS
RESULTS
After a 1-year follow-up, 19 (18.4%) participants developed recurrence of AA. Use of ACEI or ARB therapy was noted in the study population. Patients on ACEI/ARB had a greater prevalence of hypertension and coronary artery disease. On a multivariate model adjusted for baseline demographics and risk factors for AF, ACEI or ARB therapy did not prevent recurrence of AA following CBA (
CONCLUSION
CONCLUSIONS
In our study population, preablation treatment with an ACEI or ARB had no influence on the recurrence of AA following CBA for paroxysmal AF.
Identifiants
pubmed: 36339889
doi: 10.4330/wjc.v14.i10.537
pmc: PMC9627355
doi:
Types de publication
Journal Article
Langues
eng
Pagination
537-545Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors have no financial relationships to disclose.
Références
JAMA. 2014 Feb 19;311(7):692-700
pubmed: 24549549
Cardiovasc Res. 2006 Jul 1;71(1):88-96
pubmed: 16626671
Eur Heart J. 2006 Mar;27(5):512-8
pubmed: 16311236
Circ Res. 2009 Jun 19;104(12):1382-9
pubmed: 19461043
J Clin Invest. 2011 Aug;121(8):2955-68
pubmed: 21804195
Heart Rhythm. 2007 Mar;4(3 Suppl):S1-6
pubmed: 17336876
J Cardiovasc Electrophysiol. 2001 May;12(5):570-7
pubmed: 11386519
Cardiovasc Res. 2011 Mar 1;89(4):744-53
pubmed: 20962103
Heart. 2004 Sep;90(9):1025-30
pubmed: 15310691
J Am Coll Cardiol. 2008 Feb 26;51(8):802-9
pubmed: 18294563
Cardiovasc Res. 2000 Jan 14;45(2):263-6
pubmed: 10728344
Trends Pharmacol Sci. 2011 Mar;32(3):174-80
pubmed: 21316769
Arrhythm Electrophysiol Rev. 2015 May;4(1):40-3
pubmed: 26835098
Circulation. 2011 Nov 15;124(20):2264-74
pubmed: 22083148
Arq Bras Cardiol. 2016 Jan;106(1):62-9
pubmed: 26647721
Int J Cardiol. 2013 Sep 1;167(5):1807-24
pubmed: 23380698
Circulation. 2001 Feb 6;103(5):769-77
pubmed: 11156892
Prog Cardiovasc Dis. 2015 Sep-Oct;58(2):105-16
pubmed: 26162957
J Am Coll Cardiol. 2000 May;35(6):1669-77
pubmed: 10807475
Heart Rhythm. 2015 Sep;12(9):1963-71
pubmed: 26051531
Circulation. 2019 Nov 26;140(22):1779-1788
pubmed: 31630538
J Interv Card Electrophysiol. 2021 Nov;62(2):409-417
pubmed: 33206281
Am J Cardiol. 2017 Dec 1;120(11):1966-1973
pubmed: 28964382
Circulation. 2003 Jun 10;107(22):2844-9
pubmed: 12756152
Europace. 2018 Jan 1;20(1):e1-e160
pubmed: 29016840
J Mol Cell Cardiol. 1981 Sep;13(9):797-809
pubmed: 7299830
Circulation. 2002 Jul 16;106(3):331-6
pubmed: 12119249
Annu Rev Physiol. 1997;59:551-71
pubmed: 9074777